It is highly expressed in various B-cell malignancies, including ALL, diffuse large B-cell lymphoma (DLBCL), and Burkitt’s lymphoma, particularly in cases where CD19 expression is lost or downregulated [62]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.